Trial Profile
An Open Label, Randomized, Phase 2 Study of the Anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, Alone or in Combination With Tremelimumab, in Patients With Advanced and Relapsed Germ Cell Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Germ cell cancer
- Focus Therapeutic Use
- Acronyms APACHE
- 12 May 2021 Status changed from recruiting to discontinued.
- 09 Apr 2019 Planned End Date changed from 1 Aug 2019 to 1 Jun 2020.
- 09 Apr 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Dec 2019.